# Mesalazine Therapy in Patients With Irritable Bowel Syndrome

> **NCT00626288** · PHASE3 · COMPLETED · sponsor: **SOFAR S.p.A.** · enrollment: 187 (actual)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** Mesalazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00626288
- **Lead sponsor:** SOFAR S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2012-03
- **Final completion:** 2012-07
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2013-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00626288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00626288, "Mesalazine Therapy in Patients With Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00626288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*